200L GMP AAV or LVV vector batch in under 12 months on a scalable bioreactor platform.
Resilience
Resilience, Inc.: A pioneering tech-manufacturing firm ensuring access to complex medicines and safeguarding biopharma supply chains.
Founded
2020Resilience, Inc.: A pioneering tech-manufacturing firm ensuring access to complex medicines and safeguarding biopharma supply chains.
Founded in 2020, Resilience (National Resilience, Inc.) is a pioneering manufacturing and technology company with a mission to broaden access to complex medicines and protect biopharmaceutical supply chains from disruptions. The company focuses on developing advanced manufacturing technologies and processes to ensure the reliable production of critical biopharmaceuticals, including vaccines, gene therapies, and other biologics. By leveraging cutting-edge technology, Resilience aims to create a more robust and flexible biopharma infrastructure.
Notable figures affiliated with Resilience include prominent industry leaders and experts in biotechnology and pharmaceutical manufacturing. The company has attracted significant investment from high-profile venture capital firms and strategic partners, underscoring its potential impact on the industry. Key achievements include establishing state-of-the-art manufacturing facilities and forming strategic partnerships with leading biopharma companies. Resilience's efforts have significantly enhanced the stability and reliability of the biopharmaceutical supply chain, contributing to improved global health outcomes.
Companies similar to Resilience include Resilience, Resilience Therapeutics, Bright Path Laboratories and Continuity Pharma.
Resilience was founded in 2020.
Resilience's headquarters is located in Blue Ash, OH, US.
Resilience's most recent funding round was for $410M (USD) in March 2023.
As of Mar 24, 2023, Resilience has disclosed funding of $2.5B (USD). Undisclosed round amounts are excluded.
Resilience has 1,970 employees as of Feb 5, 2024.
Continuity Pharma